TIA Clinical Trials in Palo Alto, California
12 recruitingPalo Alto, California
Showing 1–12 of 12 trials
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 2
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled31 locationsNCT06661915
Recruiting
Phase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled250 locationsNCT06422806
Recruiting
Phase 3
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting
Project: Every Child for Younger Patients With Cancer
Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled167 locationsNCT06456346
Recruiting
Phase 1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Ajax Therapeutics, Inc.76 enrolled16 locationsNCT06343805
Recruiting
Clinical Procedures to Support Research in ALS
Amyotrophic Lateral SclerosisPrimary Lateral SclerosisProgressive Muscular Atrophy+1 more
University of Miami1,200 enrolled11 locationsNCT03489278
Recruiting
Phase 2
Platform Clinical Study for Conquering Scleroderma
SclerodermaInterstitial Lung Disease Due to Systemic Disease
Scleroderma Research Foundation, Inc.400 enrolled34 locationsNCT06195072
Recruiting
Phase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Cardiovascular DiseasesDementiaCognitive Impairment, Mild
Duke University20,000 enrolled103 locationsNCT04262206
Recruiting
Assessing Cognitive Decline at Home
DementiaDementia AlzheimersMild Cognitive Impairment+3 more
Stanford University25 enrolled1 locationNCT06704971
Recruiting
Not Applicable
Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor
HypertensionStrokeVascular Diseases+1 more
Stanford University50 enrolled1 locationNCT05730465